Employees: 763
Size Xizang Weixinkang Pharmaceutical (603676.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $513M, the 3636th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.87 on 18 Nov 2026.
Performance Over six months the shares fell 21.8%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue fell 8.3% over the last twelve months (peer median +9.6%); the operating margin is 16.1% (peer median 11.2%).
Valuation It trades at 2.3× enterprise value to sales against a peer median of 4.4× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 22.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.07B | CN¥1.12B | CN¥1.29B | CN¥1.31B | CN¥1.39B |
| Revenue growth | — | -13% | -2% | -5% | — |
| Gross profit | CN¥640M | CN¥654M | CN¥658M | CN¥618M | CN¥686M |
| EBITDA | n/a | CN¥269M | CN¥281M | CN¥194M | CN¥208M |
| Net income | CN¥190M | CN¥233M | CN¥246M | CN¥214M | CN¥177M |
| Free cash flow | CN¥157M | CN¥123M | CN¥339M | CN¥186M | CN¥184M |
| Capital expenditure | CN¥90.2M | CN¥83.9M | CN¥58.2M | CN¥70.8M | CN¥77.7M |
| Total debt | CN¥9.45M | CN¥11.2M | CN¥5.27M | CN¥30.1M | CN¥29.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603676.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.5% | -7.0% | 9th lowest of 20 |
| 6-month return | -21.8% | -18.4% | 7th lowest of 19 |
| Distance from 52-week high | -33.8% | -39.7% | 7th highest of 20 |
| Revenue growth (TTM) | -8.3% | +9.6% | 3rd lowest of 19 |
| Operating margin | 16.1% | 11.2% | 6th highest of 19 |
| EV / Sales | 2.3× | 4.4× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -6.1% | 8.9% | 2nd least demanding of 10 |
| Growth delivered (Del g) | +9.6% | +5.0% | 2nd highest of 10 |
| Hurdle (Req g minus delivered) | -15.7 pp | +10.0 pp | 2nd least demanding of 10 |
| ROIC minus cost of capital | +22.7 pp | -2.7 pp | 3rd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | 16.2× | 49.3% | -1.5% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 5.5× | 28.2% | +15.8% |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | 0.7× | 2.4% | +5.0% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | 6.6× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |